Mesoblast (MEOBF) EBT Margin Growth (3y) (2017 - 2023)
Powered by 
Analysis
Mesoblast (MEOBF) EBT Margin Growth (3y) (2017 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -77,617.00 |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 4.49 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 28,548.00 |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 146,420.00 |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -2.39 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 119,010.00 |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 515.00 |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 1,380.00 |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | -79,794.00 |
| Dec 31, 2022 | -20,147.00 |
| Sep 30, 2022 | -108,351.00 |
| Jun 30, 2022 | 925,424.00 |
| Mar 31, 2022 | 111,423.00 |
| Dec 31, 2021 | 73,293.00 |
| Sep 30, 2021 | -45,814.00 |
| Jun 30, 2021 | 1.03 Mn |
| Mar 31, 2021 | 90,589.00 |
| Dec 31, 2020 | -107,120.00 |
| Sep 30, 2020 | -109,173.00 |
| Mar 31, 2020 | 126,550.00 |
| Dec 31, 2019 | 326,472.00 |
| Sep 30, 2019 | 575,473.00 |
| Jun 30, 2019 | -108,792.00 |
| Mar 31, 2019 | -166,577.00 |
| Dec 31, 2018 | -91,275.00 |
| Sep 30, 2018 | 8,135.00 |
| Jun 30, 2018 | -55,336.00 |
| Mar 31, 2018 | -177,128.00 |